Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C29H30O8 |
Molecular Weight | 506.5437 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCOC1=CC2=C(C=C1)[C@@H]([C@H]([C@@H]2C3=CC=C(OC)C=C3OCCO)C(O)=O)C4=CC=C5OCOC5=C4
InChI
InChIKey=GLCKXJLCYIJMRB-UPRLRBBYSA-N
InChI=1S/C29H30O8/c1-3-11-34-19-6-7-20-22(14-19)27(21-8-5-18(33-2)15-24(21)35-12-10-30)28(29(31)32)26(20)17-4-9-23-25(13-17)37-16-36-23/h4-9,13-15,26-28,30H,3,10-12,16H2,1-2H3,(H,31,32)/t26-,27+,28+/m0/s1
Molecular Formula | C29H30O8 |
Molecular Weight | 506.5437 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/12595914Curator's Comment: description was created based on several sources, including:
http://adisinsight.springer.com/drugs/800004637 | https://www.ncbi.nlm.nih.gov/pubmed/16339819
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12595914
Curator's Comment: description was created based on several sources, including:
http://adisinsight.springer.com/drugs/800004637 | https://www.ncbi.nlm.nih.gov/pubmed/16339819
Enrasentan is an orally active mixed endothelin A/B receptor antagonist with a 100-fold greater affinity for the endothelin A receptor. In an animal model of hypertension and cardiac hypertrophy the drug has reduced blood pressure, prevented cardiac hypertrophy and preserved myocardial function. In rats with hyperinsulinemia and hypertension enrasentan normalized blood pressure and prevented cardiac and renal damage. In rats with stroke the drug reduced the ischemic area in the brain. Enrasentan had been in phase II clinical trial for the treatment of heart failure but the results suggested that enrasentan does not appear to have favorable effects on ventricular remodeling.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL252 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12595914 |
1.1 nM [Ki] | ||
Target ID: CHEMBL1785 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12595914 |
111.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
The endothelin receptor antagonist SB 217242 reduces cerebral focal ischemic brain injury. | 1995 |
|
Enrasentan, an antagonist of endothelin receptors. | 2003 Spring |
|
Endothelin receptor antagonists. | 2006 Jun |
|
Comparison of the dual receptor endothelin antagonist enrasentan with enalapril in asymptomatic left ventricular systolic dysfunction: a cardiovascular magnetic resonance study. | 2006 Jun |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16339819
60-90 mg once daily
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12595914
The functional activity of enrasentan was evaluated in vitro in rat isolated aorta. In this model enrasentan (10 to 1000 nM) produced concentration-dependent, parallel rightward shifts in the ET-1 concentration-response curve. The Kb value for inhibition of ET-1-induced contraction for enrasentan was 4.4 ± 0.6 nM. The drug was devoid of agonistic activity. In human isolated pulmonary artery enrasentan produced a 7-fold shift to the right of the ET-1 concentration-response curve, with a calculated Kb value of 5.2 nM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:11:23 GMT 2023
by
admin
on
Sat Dec 16 17:11:23 GMT 2023
|
Record UNII |
QG16H8A6ZH
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB06460
Created by
admin on Sat Dec 16 17:11:24 GMT 2023 , Edited by admin on Sat Dec 16 17:11:24 GMT 2023
|
PRIMARY | |||
|
DTXSID50168260
Created by
admin on Sat Dec 16 17:11:24 GMT 2023 , Edited by admin on Sat Dec 16 17:11:24 GMT 2023
|
PRIMARY | |||
|
300000034155
Created by
admin on Sat Dec 16 17:11:24 GMT 2023 , Edited by admin on Sat Dec 16 17:11:24 GMT 2023
|
PRIMARY | |||
|
7784
Created by
admin on Sat Dec 16 17:11:24 GMT 2023 , Edited by admin on Sat Dec 16 17:11:24 GMT 2023
|
PRIMARY | |||
|
QG16H8A6ZH
Created by
admin on Sat Dec 16 17:11:24 GMT 2023 , Edited by admin on Sat Dec 16 17:11:24 GMT 2023
|
PRIMARY | |||
|
167256-08-8
Created by
admin on Sat Dec 16 17:11:24 GMT 2023 , Edited by admin on Sat Dec 16 17:11:24 GMT 2023
|
PRIMARY | |||
|
C098288
Created by
admin on Sat Dec 16 17:11:24 GMT 2023 , Edited by admin on Sat Dec 16 17:11:24 GMT 2023
|
PRIMARY | |||
|
178103
Created by
admin on Sat Dec 16 17:11:24 GMT 2023 , Edited by admin on Sat Dec 16 17:11:24 GMT 2023
|
PRIMARY | |||
|
156258
Created by
admin on Sat Dec 16 17:11:24 GMT 2023 , Edited by admin on Sat Dec 16 17:11:24 GMT 2023
|
PRIMARY | |||
|
CHEMBL431651
Created by
admin on Sat Dec 16 17:11:24 GMT 2023 , Edited by admin on Sat Dec 16 17:11:24 GMT 2023
|
PRIMARY | |||
|
C87727
Created by
admin on Sat Dec 16 17:11:24 GMT 2023 , Edited by admin on Sat Dec 16 17:11:24 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|